Full-Time
Develops genetic medicines for neurological diseases
No salary listed
Mid
Lexington, MA, USA
Upload your resume to see how it matches 8 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Voyager Therapeutics develops genetic medicines aimed at treating neurological diseases, particularly those affecting the central nervous system like ALS. Their approach involves using a proprietary AAV (adeno-associated virus) capsid discovery platform that allows for the delivery of genetic material directly to the brain through intravenous dosing, overcoming the challenge of the blood-brain barrier. Unlike many competitors, Voyager focuses on creating treatments that are specifically designed to address severe neurological conditions and emphasizes collaboration with larger pharmaceutical companies to enhance their research and development efforts. The company's goal is to provide transformative therapies that significantly improve the lives of patients suffering from these debilitating diseases.
Company Size
51-200
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2014
Help us improve and share your feedback! Did you find this helpful?
Flexible Work Hours
In a recent press release dated February 25, 2025, Pomerantz LLP announced that it is investigating potential securities fraud claims on behalf of investors of Voyager Therapeutics, Inc. (Voyager or the Company).
Additionally, Voyager will participate in the Stifel 2025 Virtual CNS Forum, featuring a fireside chat on March 19, 2025, at 11:00 a.m. ET.
At the start of 2024, Voyager Therapeutics announced that it would collaborate with Novartis to discover and develop next-generation gene therapies for SMA and other neurologic conditions.
Great Point Partners LLC invests $12.67 million in Voyager Therapeutics, Inc. (NASDAQ:VYGR).
Voyager Therapeutics appoints Nathan Jorgensen as Chief Financial Officer.